HIND NASDAQ
Vyome Holdings, Inc.
1W: -6.4%
1M: -12.4%
3M: -14.3%
YTD: -46.2%
1Y: -65.3%
3Y: -99.9%
5Y: -100.0%
$1.91
-0.01 (-0.52%)
Weekly Expected Move ±7.3%
$2
$2
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
22 relationships22
As Filer
counterparties named
0
As Counterparty
mentioned by others
5
Rel. Types
2021-06-15
Earliest Filing
2026-02-25
Latest Filing
partner: 10
target: 5
investor: 3
acquirer: 3
supplier: 1
Counterparties (Filed by HIND)
22 relationshipsCompanies named in HIND's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| LiveChain, Inc. | LICH | partner | Indirect subsidiary of Vyome Holdings, Inc. entering agreement to acquire notes and issue stock. | 2026-02-25 | View |
| LICH AI Inc. | — | partner | Subsidiary of LiveChain, Inc. acting as the Buyer in the notes purchase agreement. | 2026-02-25 | View |
| Sociometric Solutions, Inc. | — | target | Issuer of the senior secured convertible notes being acquired; d/b/a Humanyze. | 2026-02-25 | View |
| Humanyze | — | target | Doing business name of Sociometric Solutions, Inc.; assets and operations to be transferred to Buyer. | 2026-02-25 | View |
| Remus Capital Series B II, L.P. | — | investor | Holder of the convertible notes and counterparty receiving LICH common stock. | 2026-02-25 | View |
| LiveChain, Inc. | LICH | partner | Indirect subsidiary of Vyome Holdings entering LOI to acquire convertible note from Remus | 2025-12-23 | View |
| Remus Capital Series B II, L.P. | — | investor | Holder of Sociometric Solutions convertible note and counterparty to LOI | 2025-12-23 | View |
| Maxim Group LLC | MMS | partner | Exclusive sales agent for the Company's at-the-market public offering. | 2025-08-20 | View |
| Maxim Group LLC | MMS | partner | Placement agent for the issuance and sale of common stock | 2025-06-12 | View |
| Vyome Therapeutics, Inc. | HIND | partner | Counterparty in a previously announced proposed merger | 2025-06-12 | View |
| Ninjour Health International Limited | — | partner | Counterparty in a proposed sale of substantially all assets | 2025-06-12 | View |
| Ninjour Health International Limited | — | target | Amendment to Asset Purchase Agreement reducing exercise price and extending termination date | 2025-04-28 | View |
| Ascent Partners Fund LLC | — | investor | Institutional investor entering into a senior secured convertible note agreement with the Company. | 2025-01-21 | View |
| Vyome Therapeutics, Inc. | HIND | partner | Target company in a previously announced merger with the Company. | 2025-01-21 | View |
| Vyome Therapeutics, Inc. | HIND | target | Target company in the merger with ReShape Lifesciences Inc. | 2024-07-09 | View |
| Raider Lifesciences Inc. | — | acquirer | Wholly owned subsidiary of ReShape used as the merger subsidiary. | 2024-07-09 | View |
| Ninjour Health International Limited | — | acquirer | Company acquiring ReShape's assets in the Asset Purchase Agreement. | 2024-07-09 | View |
| Biorad Medisys, Pvt. Ltd. | — | partner | Affiliate of Ninjour Health International Limited and party to a prior license agreement with ReShape. | 2024-07-09 | View |
| The Irvine Company LLC | — | supplier | Lease agreement for principal executive offices | 2023-03-21 | View |
| Maxim Group LLC | MMS | partner | Entered into an underwriting agreement to act as representative of underwriters for a firm commitment public offering of | 2023-02-10 | View |
| ReShape Lifesciences Inc. | — | target | Target company in the merger agreement with Obalon Therapeutics, Inc. | 2021-06-15 | View |
| Optimus Merger Sub, Inc. | — | acquirer | Wholly owned subsidiary of Obalon Therapeutics, Inc. used as the merger vehicle. | 2021-06-15 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-28 | Officer/Director Change; Exhibits | View | |
| 2026-08-25 | Earnings Release; Exhibits | View | |
| 2026-05-29 | Earnings Release; Exhibits | View | |
| 2026-04-29 | Bylaws Amendment; Shareholder Vote; Exhibits | View | |
| 2026-02-25 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2026-02-13 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-01-28 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-12-23 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-11-19 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-30 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-10-03 | Other Events; Financial Statements and Exhibits | View | |
| 2025-09-12 | Financial Statements and Exhibits | View | |
| 2025-09-02 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-20 | Entry into Material Definitive Agreement; Changes in Registrant's Certifying Accountant; Financial S | Agreement | View |
| 2025-08-19 | Completion of Acquisition or Disposition of Assets; Unregistered Sales of Equity Securities; Materia | Acquisition | View |
| 2025-08-11 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-07-25 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-07-15 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-07-03 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-06-18 | Other Events | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR